MRK — Merck & Co., Inc.

—
NYSE · Health Care · Pharmaceuticals · CIK 310158 ·
Last close
$143.37
Market Cap
$353.44B
52W High
$156.00
52W Low
$89.48
ADV30
9,473,245
Next earnings
2026-10-29

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 16,607,000,000 12,212,000,000 -433,000,000 -1,335,000,000 129,802,000,000 6,849,000,000 87,818,000,000
Mar 2026 16,286,000,000 12,091,000,000 -3,201,000,000 -4,240,000,000 128,685,000,000 5,327,000,000 82,754,000,000
Dec 2025 16,400,000,000 10,849,000,000 4,065,000,000 2,963,000,000 136,866,000,000 14,565,000,000 84,204,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$18,703,000,000
Investing CF
$-28,332,000,000
Financing CF
$1,100,000,000
CapEx
$-3,957,000,000
Dividends Paid
$-8,366,000,000
Buybacks
$-3,536,000,000
EPS Diluted TTM
$0.97
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$66,223,000,000
Inventory
$6,164,000,000
Receivables
$12,744,000,000
ST Investments
$100,000,000
EBIT TTM
$6,723,000,000
Pretax Income TTM
$4,762,000,000
Interest Exp TTM
$1,961,000,000
Analysts
26

Yahoo Snapshot (yfinance, live)

Total Revenue
$67,377,999,872
EBITDA
$29,492,000,768
Free Cash Flow
$14,024,250,368
Enterprise Value
$406,031,499,264
Total Cash
$9,649,999,872
Total Debt
$53,902,999,552
Shares Out
2,465,245,688
Trailing EPS
$0.99
Book Value
$18.20
ROE
5.1%
ROA
11.3%
Div Yield
2.32%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 65,011,000,000 22,107,000,000 18,254,000,000 136,866,000,000 84,204,000,000 52,606,000,000 16,472,000,000
Dec 2024 64,168,000,000 20,221,000,000 17,117,000,000 117,106,000,000 70,734,000,000 46,313,000,000 21,468,000,000
Dec 2023 60,115,000,000 2,954,000,000 365,000,000 106,675,000,000 69,040,000,000 37,581,000,000 13,006,000,000
Dec 2022 59,283,000,000 18,282,000,000 14,519,000,000 109,160,000,000 63,102,000,000 45,991,000,000 19,095,000,000

TTM Snapshot

Revenues TTM
$66,569,000,000
NetIncome TTM
$3,173,000,000
OpCashFlow TTM
—
Assets (Latest)
$129,802,000,000
Forward EPS
$8.98

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $140.00 · spot: $137.78 · call volume: 10,630 · put volume: 1,054
Expected Move to 2027-01-15: ±$13.79 (10.01%) — implied range $123.99 – $151.57 · ATM straddle on $140.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
NVS NOVARTIS AG $302.46B $159.13 —
AZN ASTRAZENECA PLC $282.68B $182.27 —
ABBV AbbVie Inc. $517.59B $292.82 —
JNJ JOHNSON & JOHNSON $670.92B $278.70 —
ABT ABBOTT LABORATORIES $181.35B $104.71 —

News headlines (Yahoo Finance, 1h cache)

What Does Merck (MRK) Losing Nemtabrutinib Mean For Its Blood Cancer Pipeline?
2026-11-19 00:14 · Yahoo
Top Stock Reports for Merck, Caterpillar & Union Pacific
2026-11-18 20:27 · Yahoo
Merck Ends Nemtabrutinib Development: What's Next for Its Pipeline?
2026-11-18 14:36 · Yahoo
Allergy Clinical Trial Services Global Market Report 2026: $1.66 Billion Forecast to 2030 | Capitalize on AI and Remote Trials with J&J, Merck, Sanofi, Novartis, and GSK
2026-11-18 14:35 · Yahoo
Thomas H. Glocer to Retire From Merck Board of Directors in May 2027; Douglas M. Baker, Jr. Appointed Independent Lead Director
2026-11-18 11:45 · Yahoo
Merck Announces Update on BELLWAVE Clinical Development Program Evaluating Nemtabrutinib
2026-11-17 21:15 · Yahoo
How Investors May Respond To Merck (MRK) Pipeline Progress
2026-11-17 17:13 · Yahoo
Merck Announces First-Quarter 2027 Dividend
2026-11-17 15:01 · Yahoo
Merck Stock's $1.3 Billion China Problem Goes Quiet
2026-11-17 14:40 · Yahoo
Moderna Targets Year-End Cancer Therapy Filing, Sees Multibillion-Dollar Opportunity
2026-11-18 13:13 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.